DICE Therapeutics (NASDAQ:DICE) Shares Gap Down to $19.09

DICE Therapeutics, Inc. (NASDAQ:DICEGet Rating)’s share price gapped down prior to trading on Wednesday . The stock had previously closed at $19.09, but opened at $18.70. DICE Therapeutics shares last traded at $19.05, with a volume of 2,472 shares traded.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. HC Wainwright assumed coverage on DICE Therapeutics in a research report on Monday, July 18th. They issued a “buy” rating and a $40.00 target price for the company. Cantor Fitzgerald began coverage on DICE Therapeutics in a report on Wednesday, September 14th. They set an “overweight” rating and a $36.00 price objective for the company. Finally, Stifel Nicolaus began coverage on DICE Therapeutics in a report on Tuesday, September 6th. They set a “buy” rating and a $37.00 price objective for the company. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $43.33.

DICE Therapeutics Price Performance

The company has a fifty day simple moving average of $18.47 and a two-hundred day simple moving average of $17.73. The company has a market capitalization of $701.17 million and a P/E ratio of -4.80.

Hedge Funds Weigh In On DICE Therapeutics

Institutional investors have recently made changes to their positions in the business. Cutler Group LP bought a new position in shares of DICE Therapeutics in the first quarter worth about $279,000. Virtus ETF Advisers LLC bought a new position in shares of DICE Therapeutics in the fourth quarter worth about $169,000. Northpond Ventures LLC bought a new position in shares of DICE Therapeutics in the fourth quarter worth about $83,343,000. Deep Track Capital LP bought a new position in shares of DICE Therapeutics in the fourth quarter worth about $33,941,000. Finally, TD Asset Management Inc. increased its stake in shares of DICE Therapeutics by 20.7% in the first quarter. TD Asset Management Inc. now owns 57,226 shares of the company’s stock worth $1,095,000 after purchasing an additional 9,800 shares during the period. 95.42% of the stock is currently owned by institutional investors.

DICE Therapeutics Company Profile

(Get Rating)

DICE Therapeutics, Inc, a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics.

Recommended Stories

Receive News & Ratings for DICE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DICE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.